Maxtreme Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -49.14%
- Ebitda -49.14%
- Net Worth -1069.95%
- Total Assets -83.93%
About Maxtreme Pharma
Maxtreme Pharma Limited (MPL) is a Public Limited Indian Non-Government Company incorporated in India on 03 September 2015 (Nine years and five months 0 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjeev Kumar, Gaurav Chawla, and Gulzar Singh serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51501MH2015PLC268068
-
Company No.
268068
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
03 Sep 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Maxtreme Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Kumar
|
Director | 03-Sep-2015 | Current |
|
Gaurav Chawla
|
Director | 03-Sep-2015 | Current |
|
Gulzar Singh
|
Director | 03-Sep-2015 | Current |
Financial Performance of Maxtreme Pharma.
Maxtreme Pharma Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 49.14% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1069.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxtreme Pharma?
In 2019, Maxtreme Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Rescuers Life Sciences LimitedGaurav Chawla is a mutual person
-
Health Biotech LimitedGaurav Chawla is a mutual person
-
Coral Pharmaceuticals Private LimitedGulzar Singh is a mutual person
-
Cloudncloud Tech LimitedSanjeev Kumar and Gulzar Singh are mutual person
-
Maxgars Llp
Gaurav Chawla is a mutual person
-
Maxgars Nutraceuticals Limited
Gaurav Chawla is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maxtreme Pharma?
Unlock and access historical data on people associated with Maxtreme Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxtreme Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxtreme Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.